You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Dual-view endoscopic probe

    SBC: Omniscient Imaging, Inc.            Topic: 102

    DESCRIPTION provided by applicant Colon cancer is a leading cause of cancer death in the United States and overseas Colonoscopy is the preferred screening method at an estimated annual cost of over $ billion in the US Unfortunately many lesions are missed because pre cancerous growths remain hidden from view behind folds and flexures of the colon Current methods of increasing the field of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development

    SBC: NUVOX PHARMA, L.L.C.            Topic: 394

    DESCRIPTION provided by applicant Pancreatic ductal adenocarcinoma PDAC is a deadly form of cancer and patient survival depends upon the stage of diagnosis While overall survival at diagnosis is only about months of patients with stage I disease survive years The best currently available diagnostic test which is routinely performed in patients at high risk for PDAC is endoscop ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of nucleic acid delivery platform based on polymeric CXCR4 antagonists

    SBC: Bohemica Pharmaceuticals, LLC            Topic: 100

    DESCRIPTION provided by applicant Therapeutics based on nucleic acids NA promise to revolutionize treatment of multiple diseases but their widespread use is currently limited by the lack of efficient delivery methods We have recently developed a new NA delivery platform based on polymeric CXCR inhibitors PCX suitable as dual function systems for simultaneous NA delivery and inhibition of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Mutation Enriched Targeted Re Sequencing

    SBC: TRANSGENOMIC, INC.            Topic: 103

    DESCRIPTION provided by applicant Low level tumor associated somatic DNA mutations can have profound implications for development of metastasis prognosis choice of treatment follow up or early cancer detection Unless they are effectively detected these low level mutations can misinform patient management decisions or become missed opportunities for personalized medicine Widely used tech ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Single-Molecule Analyte Detection by Molecular Motor-driven Nanodevices

    SBC: Attometrics            Topic: NIGMS

    DESCRIPTION provided by applicant There is an urgent need for a platform technology that can monitor changes in metabolite and protein biomarkers below current detection limits because in many cases the disease has progressed to an advanced state by the time the abundance of the biomarker has become measurable Our molecular motor powered nanodevice linked immunosorbent assay MONA LISA is ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Combinatorial Inactivation of ERBB Receptors in Breast Cancer using Therapeutic Stapled Peptides

    SBC: ARIZONA CANCER THERAPEUTICS L.L.C.            Topic: 103

    DESCRIPTION provided by applicant In metastatic breast cancer the Epidermal Growth Factor Receptor family of transmembrane tyrosine kinases ErbB drives proliferation and metastasis EGFR HER and ErbB are known to be highly expressed and active in both the HER and Triple Negative Basal subtypes of breast cancer and have been targeted with varying effectiveness Importantly targeting of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted and Non-targeted Microbubbles for Pediatric Applications

    SBC: NUVOX PHARMA, L.L.C.            Topic: NICHD

    Project Summary Staphylococcus is the most common cause of community and hospital acquired infective endocarditis worldwide Staphylococcal S aureus endocarditis is a serious health problem in children and adults that carries high morbidity and mortality The incidence of this disease is increasing due to healthcare advances with widespread use ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Ultrahigh Performance Non-Denaturing Protein Chromatography Columns

    SBC: BIOVIDRIA, INC.            Topic: 400

    PROJECT SUMMARY The proposed product is an analytical scale UHPLC column for separating protein drugs in native form with the Phase I proposal focused on anion exchange chromatography as the separation mechanism The bonded phase is made of polymer chains in this case bearing weak anion exchange groups The study will be expanded to cation exchange and hydrophobic interaction chromatography in ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    ABSTRACT Breast cancer is the second leading cause of cancer deaths in women in the United States and early detection can help improve survival While mammography is the current first line imaging technique for early breast cancer detection its diagnostic accuracy is limited in women with dense breast tissue Ultrasound is often performed as a second line test in women with dense breast tissue H ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Ultrasensitive SERS Nano-Sensors for Pancreatic Cancer Diagnosis and Prognosis

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: 103

    ABSTRACT Pancreatic cancer PC is an extremely aggressive malignancy with one of the worst prognoses of all cancers with a median survival of less than one year and an overall year survival of andlt With marked resistance to chemo and radiotherapies surgery is the only curative option In patients with localized disease and no lymph node or extra pancreatic metastases complete surgical ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government